ArticleFrontiers in medicine2025
Ovarian lipid metabolic alterations in polycystic ovary syndrome: insights from proton magnetic resonance spectroscopy.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- High prevalence of poly cystic ovary syndrome among young Saudi medical students: an observational cross-sectional study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Altered ovarian lipid metabolism plays a critical role in the pathophysiology of polycystic ovary syndrome (PCOS). This study aimed to evaluate and compare ovarian lipid metabolic profiles in PCOS patients and healthy controls using proton magnetic resonance spectroscopy ( Method: This was a single-center prospective study. Single-voxel Results: Significant elevations were observed in lipid metabolites MM09 + Lip09, MM14 + Lip13a + Lip13b + MM12, MM21 + Lip21, Lip23, and Lip28 (e.g., MM09, macromolecule signal at 0.9 ppm; Lip09, lipid signal at 0.9 ppm) in PCOS patients compared to controls. The combination model of key lipids achieved an AUC of 0.89 [95% confidence interval (CI): 0.83-0.95], with sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 0.76, 0.95, 0.95, and 0.76, respectively, in the training cohort, and 0.88 (95% CI, 0.80-0.95), 0.76, 0.87, 0.84, and 0.81, respectively, in the test cohort. Pathway enrichment analysis revealed significant involvement of fatty acid metabolism, phospholipid synthesis, lipid signaling, and membrane organization pathways. Conclusion: The study highlights significant lipid metabolic disruptions in PCOS. Lip23 and Lip28 emerged as potential biomarkers for PCOS diagnosis. These findings enhance the understanding of PCOS pathophysiology and provide a foundation for future targeted therapeutic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.